Savient Pharmaceuticals appoints president of Savient Europe
David Veitch takes up the role
Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.
Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.
Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.
Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)
With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Manufacturing
Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories
The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.